Evidence map›Paper›PMID 30530753›Full record

ArticleBlood advances2018

Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.

Chia-Ching Wang, Cassandra Thanh, Erica A Gibson, Maya Ball-Burack, Louise E Hogan, Benjamin Descours, Norman Jones, Alexander B Carvidi, Sadie Munter, Sonia Bakkour and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Immunotherapy in People With HIV and Cancer.Frontiers in immunology · 2019
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chia-Ching WangDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Cassandra ThanhDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Erica A GibsonDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Maya Ball-BurackDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Louise E HoganDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Benjamin DescoursMolecular Virology Unit, Human Genetic Institute, Centre National de la Recherche Scientifique, Montpellier, France; and.
Norman JonesDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Alexander B CarvidiDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Sadie MunterDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Sonia BakkourBlood Systems Research Institute, San Francisco, CA.
Michael P BuschBlood Systems Research Institute, San Francisco, CA.
Jeffrey M MilushDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Steven G DeeksDepartment of Medicine, University of California San Francisco, San Francisco, CA.
Timothy J HenrichDepartment of Medicine, University of California San Francisco, San Francisco, CA.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Targeting latent HIV-1 Reservoirs with the Antibody-Drug Conjugate, Brentuximab VedotinR33AI116205 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2016 to 2018
$1.2M
NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI141003NIAID NIH HHS R33 AI116205NIAID NIH HHS U19 AI096109
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAnti-Retroviral AgentsBrentuximab VedotinCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHIV-1HIV InfectionsHodgkin DiseaseHumansImmunoconjugatesImmunophenotypingKi-1 AntigenMaleRNA, ViralAnti-Retroviral AgentsBrentuximab VedotinImmunoconjugatesKi-1 AntigenRNA, Viral

Identifiers

PMID30530753
PMCPMC6290106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.